Bristol-Myers Squibb Co BMY is higher in early trading after the company announced that Phase III study of Opdivo was stopped early after the trial "met its endpoint," according to a press release from the company. Opdivo "demonstrated superior overall survival" in patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Opdivo received approval from the U.S. Food and Drug Administration as a monotherapy in two cancer indications. Bristol-Myers said that patients in the trial will have the opportunity to continue or start treatment with Opdivo.
Bristol-Myers is 3.2 percent higher at last trade of $65.72. The stock has gained 11 percent this year and 32 percent over the prior 52 weeks. The company is still below its all-time peak around $80 per share hit in 1999.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.